These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
347 related items for PubMed ID: 32950641
1. Integration of genetic variants and gene network for drug repurposing in colorectal cancer. Irham LM, Wong HS, Chou WH, Adikusuma W, Mugiyanto E, Huang WC, Chang WC. Pharmacol Res; 2020 Nov; 161():105203. PubMed ID: 32950641 [Abstract] [Full Text] [Related]
2. Use of genome-wide association studies for cancer research and drug repositioning. Zhang J, Jiang K, Lv L, Wang H, Shen Z, Gao Z, Wang B, Yang Y, Ye Y, Wang S. PLoS One; 2015 Nov; 10(3):e0116477. PubMed ID: 25803826 [Abstract] [Full Text] [Related]
3. Identification of novel biomarkers and small molecule drugs in human colorectal cancer by microarray and bioinformatics analysis. Chen J, Wang Z, Shen X, Cui X, Guo Y. Mol Genet Genomic Med; 2019 Jul; 7(7):e00713. PubMed ID: 31087508 [Abstract] [Full Text] [Related]
4. Drug Repurposing for Atopic Dermatitis by Integration of Gene Networking and Genomic Information. Adikusuma W, Irham LM, Chou WH, Wong HS, Mugiyanto E, Ting J, Perwitasari DA, Chang WP, Chang WC. Front Immunol; 2021 Jul; 12():724277. PubMed ID: 34721386 [Abstract] [Full Text] [Related]
5. Integration of genomic variants and bioinformatic-based approach to drive drug repurposing for multiple sclerosis. Afief AR, Irham LM, Adikusuma W, Perwitasari DA, Brahmadhi A, Chong R. Biochem Biophys Rep; 2022 Dec; 32():101337. PubMed ID: 36105612 [Abstract] [Full Text] [Related]
6. Identification of Prognostic Biomarker Signatures and Candidate Drugs in Colorectal Cancer: Insights from Systems Biology Analysis. Rahman MR, Islam T, Gov E, Turanli B, Gulfidan G, Shahjaman M, Banu NA, Mollah MNH, Arga KY, Moni MA. Medicina (Kaunas); 2019 Jan 17; 55(1):. PubMed ID: 30658502 [Abstract] [Full Text] [Related]
7. Identifying the key genes and microRNAs in colorectal cancer liver metastasis by bioinformatics analysis and in vitro experiments. Zhang T, Guo J, Gu J, Wang Z, Wang G, Li H, Wang J. Oncol Rep; 2019 Jan 17; 41(1):279-291. PubMed ID: 30542696 [Abstract] [Full Text] [Related]
8. Discovery of the Anti-Tumor Mechanism of Calycosin Against Colorectal Cancer by Using System Pharmacology Approach. Huang C, Li R, Shi W, Huang Z. Med Sci Monit; 2019 Jul 28; 25():5589-5593. PubMed ID: 31352466 [Abstract] [Full Text] [Related]
9. Novel diagnostic and prognostic biomarkers of colorectal cancer: Capable to overcome the heterogeneity-specific barrier and valid for global applications. Hameed Y, Usman M, Liang S, Ejaz S. PLoS One; 2021 Jul 28; 16(9):e0256020. PubMed ID: 34473751 [Abstract] [Full Text] [Related]
10. The identification of a common different gene expression signature in patients with colorectal cancer. Zhao ZW, Fan XX, Yang LL, Song JJ, Fang SJ, Tu JF, Chen MJ, Zheng LY, Wu FZ, Zhang DK, Ying XH, Ji JS. Math Biosci Eng; 2019 Apr 10; 16(4):2942-2958. PubMed ID: 31137244 [Abstract] [Full Text] [Related]
11. Identification of candidate biomarkers and therapeutic drugs of colorectal cancer by integrated bioinformatics analysis. Zheng Z, Xie J, Xiong L, Gao M, Qin L, Dai C, Liang Z, Wang Y, Xue J, Wang Q, Wang W, Li X. Med Oncol; 2020 Oct 19; 37(11):104. PubMed ID: 33078282 [Abstract] [Full Text] [Related]
12. Identification of intestinal flora-related key genes and therapeutic drugs in colorectal cancer. Zhang J, Zhang H, Li F, Song Z, Li Y, Zhao T. BMC Med Genomics; 2020 Nov 16; 13(1):172. PubMed ID: 33198757 [Abstract] [Full Text] [Related]
13. Integrative Bioinformatics Analysis: Unraveling Variant Signatures and Single-Nucleotide Polymorphism Markers Associated with 5-FU-Based Chemotherapy Resistance in Colorectal Cancer Patients. Askari M, Mirzaei E, Navapour L, Karimpour M, Rejali L, Sarirchi S, Nazemalhosseini-Mojarad E, Nobili S, Cava C, Sadeghi A, Fatemi N. J Gastrointest Cancer; 2024 Dec 16; 55(4):1607-1619. PubMed ID: 39240276 [Abstract] [Full Text] [Related]
14. A network-based predictive gene expression signature for recurrence risks in stage II colorectal cancer. Yang WJ, Wang HB, Wang WD, Bai PY, Lu HX, Sun CH, Liu ZS, Guan DK, Yang GW, Zhang GL. Cancer Med; 2020 Jan 16; 9(1):179-193. PubMed ID: 31724326 [Abstract] [Full Text] [Related]
15. Identification of potential hub genes via bioinformatics analysis combined with experimental verification in colorectal cancer. Zhou H, Yang Z, Yue J, Chen Y, Chen T, Mu T, Liu H, Bi X. Mol Carcinog; 2020 Apr 16; 59(4):425-438. PubMed ID: 32064687 [Abstract] [Full Text] [Related]
16. Integrative analyses of molecular pathways and key candidate biomarkers associated with colorectal cancer. Pirim D. Cancer Biomark; 2020 Apr 16; 27(4):555-568. PubMed ID: 32176635 [Abstract] [Full Text] [Related]
17. TNK2 as a key drug target for the treatment of metastatic colorectal cancer. Qi L, Ding Y. Int J Biol Macromol; 2018 Nov 16; 119():48-52. PubMed ID: 30036625 [Abstract] [Full Text] [Related]
18. Identification of disrupted pathways in ulcerative colitis-related colorectal carcinoma by systematic tracking the dysregulated modules. Wu D, Li Q, Song G, Lu J. J BUON; 2016 Nov 16; 21(2):366-74. PubMed ID: 27273946 [Abstract] [Full Text] [Related]
19. Delineating the underlying molecular mechanisms and key genes involved in metastasis of colorectal cancer via bioinformatics analysis. Qi C, Chen Y, Zhou Y, Huang X, Li G, Zeng J, Ruan Z, Xie X, Zhang J. Oncol Rep; 2018 May 16; 39(5):2297-2305. PubMed ID: 29517105 [Abstract] [Full Text] [Related]
20. ASPM is a Novel Candidate Gene Associated with Colorectal Cancer Cell Growth. Yang Q, Qi M, Chen Y, Tian S, Liao F, Dong W. DNA Cell Biol; 2021 Jul 16; 40(7):921-935. PubMed ID: 34042518 [Abstract] [Full Text] [Related] Page: [Next] [New Search]